Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy HTG Molecular Diagnostics stock | $0.276

Own HTG Molecular Diagnostics stock in just a few minutes.

Fact checked

HTG Molecular Diagnostics, Inc is a diagnostics & research business based in the US. HTG Molecular Diagnostics shares (HTGM) are listed on the NASDAQ and all prices are listed in US Dollars. HTG Molecular Diagnostics employs 108 staff and has a trailing 12-month revenue of around USD$10.8 million.

How to buy shares in HTG Molecular Diagnostics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for HTG Molecular Diagnostics. Find the stock by name or ticker symbol: HTGM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until HTG Molecular Diagnostics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.276, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of HTG Molecular Diagnostics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of HTG Molecular Diagnostics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

HTG Molecular Diagnostics share price

Use our graph to track the performance of HTGM stocks over time.

HTG Molecular Diagnostics shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$0.276
52-week rangeUSD$3.78 - USD$13.8
50-day moving average USD$4.9262
200-day moving average USD$6.6936
Wall St. target priceUSD$12.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.6

Buy HTG Molecular Diagnostics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy HTG Molecular Diagnostics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

HTG Molecular Diagnostics price performance over time

Historical closes compared with the close of $0.276 from 2020-11-16

1 week (2021-01-07) -95.75%
1 month (2020-12-17) -94.46%
3 months (2020-10-16) -15.34%
6 months (2020-07-16) -52.94%
1 year (2020-01-16) -58.81%
2 years (2019-01-16) -87.79%
3 years (2018-01-16) 3.5
5 years (2016-01-15) 4.21

HTG Molecular Diagnostics financials

Revenue TTM USD$10.8 million
Gross profit TTM USD$-277,709
Return on assets TTM -28.35%
Return on equity TTM -94.63%
Profit margin -194.78%
Book value $2.277
Market capitalisation USD$23.1 million

TTM: trailing 12 months

Shorting HTG Molecular Diagnostics shares

There are currently 120,329 HTG Molecular Diagnostics shares held short by investors – that's known as HTG Molecular Diagnostics's "short interest". This figure is 10.6% up from 108,785 last month.

There are a few different ways that this level of interest in shorting HTG Molecular Diagnostics shares can be evaluated.

HTG Molecular Diagnostics's "short interest ratio" (SIR)

HTG Molecular Diagnostics's "short interest ratio" (SIR) is the quantity of HTG Molecular Diagnostics shares currently shorted divided by the average quantity of HTG Molecular Diagnostics shares traded daily (recently around 143248.80952381). HTG Molecular Diagnostics's SIR currently stands at 0.84. In other words for every 100,000 HTG Molecular Diagnostics shares traded daily on the market, roughly 840 shares are currently held short.

However HTG Molecular Diagnostics's short interest can also be evaluated against the total number of HTG Molecular Diagnostics shares, or, against the total number of tradable HTG Molecular Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case HTG Molecular Diagnostics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 HTG Molecular Diagnostics shares in existence, roughly 50 shares are currently held short) or 0.0499% of the tradable shares (for every 100,000 tradable HTG Molecular Diagnostics shares, roughly 50 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against HTG Molecular Diagnostics.

Find out more about how you can short HTG Molecular Diagnostics stock.

HTG Molecular Diagnostics share dividends

We're not expecting HTG Molecular Diagnostics to pay a dividend over the next 12 months.

Have HTG Molecular Diagnostics's shares ever split?

HTG Molecular Diagnostics's shares were split on a 1:15 basis on 23 November 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your HTG Molecular Diagnostics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for HTG Molecular Diagnostics shares which in turn could have impacted HTG Molecular Diagnostics's share price.

HTG Molecular Diagnostics share price volatility

Over the last 12 months, HTG Molecular Diagnostics's shares have ranged in value from as little as $3.78 up to $13.8. A popular way to gauge a stock's volatility is its "beta".

HTGM.US volatility(beta: 1.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HTG Molecular Diagnostics's is 1.6824. This would suggest that HTG Molecular Diagnostics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

HTG Molecular Diagnostics overview

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq path assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq ALKPlus assay EU;HTG EdgeSeq precision immuno-oncology panel; HTG lung fusions assay; HTG autoimmune panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site